Brexucabtagene autoleucel

{
  "id": "MLC-T-ONC-001250",
  "term": "Brexucabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with mantle cell lymphoma or B-cell acute lymphoblastic leukemia that came back or did not get better after other treatment. It is also being studied in the treatment of other types of cancer. Brexucabtagene autoleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Brexucabtagene autoleucel binds to a protein called CD19, which is found on some lymphoma cells and leukemia cells. This helps the body’s immune system kill cancer cells. Brexucabtagene autoleucel is a type of CAR T-cell therapy. Also called Tecartus.",
    "A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of abrexucabtagene autoleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development. KTE-X19 has the same construct as axicabtagene ciloleucel, but differs in the manufacturing process in that KTE-X19 includes specific T-cell selection and lymphocyte enrichment necessary for activity against certain B-cell malignancies."
  ],
  "synonyms": [
    "Tecartus",
    "Brexu-cel",
    "anti-CD19 autologous CAR-CD28 T cells KTE-X19",
    "anti-CD19 autologous CAR-CD28 T-cells KTE-X19"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/brexucabtagene-autoleucel/"
}